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We prospectively studied the clinical eﬃcacy of an alternative cancer treatment “Psorinum Therapy” in treating stomach, gall
bladder, pancreatic and liver cancers. Our study was observational, open level and single arm. The participants’ eligibility criteria
included histopathology/cytopathology conﬁrmation of malignancy, inoperable tumor, and no prior chemotherapy or radiation
therapy. The primary outcome measures of the study were (i) to assess the radiological tumor response (ii) to ﬁnd out how many
participants survived at least 1 year, 2 years, 3 years, 4 years and ﬁnally 5 years after the beginning of the study considering each
type of cancer. Psorinum-6x was administered orally to all the participants up to 0.02ml/Kg body weight as a single dose in
empty stomach per day for 2 years along with allopathic and homeopathic supportive cares. 158 participants (42 of stomach, 40
of gall bladder, 44 of pancreatic, 32 of liver) were included in the ﬁnal analysis of the study. Complete tumor response occurred
in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases. Double-blind randomized controlled clinical trial
should be conducted for further scientiﬁc exploration of this alternative cancer treatment.
1.Introduction
Although, great advances have been made in the treatment
o fs o m ef o r m so fc a n c e ra n dn e wa d v a n c e si ns u r g e r y ,
radiotherapy, and chemotherapy leading to an increase in
cure rates have been achieved, such interventions are often
too much expensive and beyond the reach of many cancer
patients of the developing as well as of the developed coun-
tries [1–3]. In developing countries, majority of the cancer
patients have inadequate access to the mainstream cancer
treatments due to lack of proper medical infrastructures,
skills, and above all limited ﬁnancial resources [4, 5]. Some
types of cancer (i.e., liver, gall bladder, pancreatic, and stom-
ach) are still associated with poor prognosis to conventional
cancer treatments [6–9]. Side eﬀects of the chemotherapy
and radiation therapy are also intolerable to many cancer
patients [10–12]. In most of the situations, elderly can-
cer patients cannot be provided with conventional cancer
treatments because of old age-related problems [13, 14].
As a result, alternative cancer treatments have become an
important feature of oncology regardless of geographic
region and they appear to exist in greater abundance
through out the world. Many alternative cancer therapeutic
modalities are now being practiced in India, and one ofthem
which has gained signiﬁcant popularity is called Psorinum
Therapy [15–17].The investigationalanticancerdrugusedin
thisalternativecancertherapyis“Psorinum” whichisderived
from the sphere of homeopathy. The supportive treatments
of Psorinum Therapy are adopted both from the spheres of
allopathy and homeopathy. Psorinum is an alcoholic extract
of the scabies, slough, and pus cells. According to the pre-
clinical data, “Psorinum-6x” (“x” stands for decimal potency
of homeopathy) activates diﬀerent immune eﬀector cells
(e.g., T cells, and accessory cells like, macrophages, dendritic
cells, and natural killer cells) which can trigger a complex
antitumor immune response [18, 19]. In a rat model study,
daily oral administration of Psorinum 6x at doses up to
0.5ml/Kgbody weight/day for2 weeks resulted inno adverse2 Evidence-Based Complementary and Alternative Medicine
side eﬀect [19]. Published retrospective and prospective
studies also support the eﬃcacy of Psorinum Therapy in
treating patients with various malignancies [20–28]. The
prospective observational clinical trial, reported here, was
conducted to evaluate the eﬃcacy of the Psorinum Therapy
in treating stomach, gall bladder, pancreatic, and liver
cancers and to assess the side eﬀects of the drug Psorinum if
any [29].
2.Materialsand Methods
2.1. Settings. The study was conducted by the Critical Can-
cer Management Research Centre and Clinic (CCMRCC)
situated in Kolkata of West Bengal, India. The study started
from June 2001 and completed in July 2009. The study
protocol was approved by the Institutional Review Board
(IRB approval Number: 2001–05) of the CCMRCC in
conformity with the World Medical Association (WMA)
declaration of Helsinki and it is subsequent amendments
and the ethical guidelines of the Indian Council of Medical
Research (ICMR) for the biomedical research on human
participants.
2.2. Study Design. The study was prospective, observational,
open level, and single arm.
2.3. Inclusion and Exclusion Criteria. Only the patients of
conﬁrmed malignancy (by histopathological examination
of endoscopic biopsy, cytopathological exam of CT guided
FNAC) involving stomach, gall bladder, pancreatic, and
liver cancers of both sexes were enrolled. The participants’
eligibility criteria included (i) histopathology/cytopathology
conﬁrmation of malignancy, (ii) inoperable tumors, and
(iii) no prior chemotherapy or radiation therapy. The lower
agelimitwas18yearsandtherewasnoupperagelimitforthe
eligibility. Patients who were unable to understand English,
Hindi, or Bengali or resided outside India were excluded
from the study. The patients who reported the cancer
centre from the period of June 2001 to November 2003
and fulﬁlled the eligibility criteria were recruited. Written
informed signed consent was taken from each patient before
starting the study.
2.4.Intervention. Psorinum-6x wasadministered orallytoall
theparticipantsupto0.02ml/Kgbodyweightasasingledose
in empty stomach per day for complete course duration of 2
years.
2.5. Supportive Treatments. In this study, the supportive
cares were taken both from the spheres of allopathy and
homeopathy. Supportive cares for control of infection, pain,
electrolytic balance, bleeding, nutritional deﬁciencies were
taken, and blood transfusion, abdominal or plural para-
centesis, analgesic, bronchodilator, stenting of the hepato-
pancreato-biliary system, and bypass were done as and when
required to improve the survival and the quality of life of the
participants.Thefrequentlyusedhomeopathicmedicinesfor
the purpose of the supportive cares were Chelidonium majus,
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Figure1:Distributionofpartialandcompletetumorresponserates
in diﬀerent cancer types.
Carduus marianus, Baryta carbonica, Conium maculatum,
Carbo animalis, Bryonia alba, Medorrhinum, Thuja occiden-
talis, Cholesterinum,andLycopodiumclavatum(Table1).Less
frequently used homeopathic medicines for the purpose of
the supportive cares were mother tincture of the Berberis
vulgaris, mother tincture of the Calendula oﬃcinalis,m o t h e r
tincture of the Hamamelis virginiana,m o t h e rt i n c t u r eo f
the Symphytum oﬃcianale, mother tincture of the Syzygium
jambolanum, Gelsemium 200c, Cantharides 200c, Sulphur
200c, Arsenicum album 200c, and Causticum 200c.
2.6. Outcome Measures. Primary outcome measures of the
study were (i) to assess the radiological tumor response and
(ii) to ﬁnd out in each type of cancer how many participants
survived at least 1 year, 2 years, 3 years, 4 years, and ﬁnally,
after 5 years since the beginning of the study. To assess the
radiological tumor response, CT Scans were done at the
beginning of the study, repeated every 3–6 months during
the 1st year of the study and repeated every 6–8 months
during the next 2 years of the study. Radiological tumor
response was deﬁned by Response Evaluation Criteria in
Solid Tumors (RECIST). A complete response was deﬁned
as complete disappearance of all targeted lesions without
disease progression or any new lesion, and a partial response
was deﬁned as at least 30% regression in the sum of the
longest diameter of the targeted lesions as reference to the
baseline sum LD without disease progression or any new
lesion. To assess the survival, the investigators followed up
theparticipants viapersonalmeetings, phonecalls,andmails
at least for 5 years (where applicable) after the study began.
Secondary outcome measure of the study was to assess the
side eﬀects of the Psorinum. The investigators asked the
participants and also examined them clinically to assess if
they had any side eﬀect. Apart from these, participants were
also followed up to know if they were taking any other
conventional or investigational cancer treatments.
3.Results
10 (5.95%) participants were dropped out from the study
as they opted for conventional cancer treatments, amongEvidence-Based Complementary and Alternative Medicine 3
Table 1: Details of the frequently used homeopathic medicines for the purpose of the supportive cares.
Name Origin Dosing Power Used to control ailments
(1) Chelidonium majus Herb-Chelidonium majus Up to 0.04ml/Kg body
weight/day orally Mother tincture (1) Abnormalliver functions
(2) Dysponea
(2) Carduus marianus Herb-Carduus marianus Up to 0.04ml/Kg body
weight/day orally Mother tincture (1) Abnormalliver function
(2) Cholestasis
(3) Baryta carbonica Barium carbonate Up to 0.02ml/Kg body
weight/day orally 200c (1) Anaemia
(2) Cancer-related pain
(4) Conium maculatum Herb-Conium maculatum Up to 0.02ml/Kg body
weight/day orally 200c (1)Heart troubles
(2) Abnormalblood pressure
(5) Carbo animalis Animal charcoal Up to 0.02ml/Kg body
weight/day orally 200c (1) Cough
(2) Constipation
(6) Bryonia alba Herb-Bryonia alba Up to 0.02ml/Kg body
weight/day orally 200c (1) Dysponea
(2) Cancer-related pain
(7) Medorrhinum Gonorrhoeal cocci Up to 0.02ml/Kg body
weight/day orally 200c (1) Abnormalblood sugar
(2) Cancer-related pain
(8) Thuja occidentalis Herb-Thuja occidentalis Up to 0.02ml/Kg body
weight/day orally Mother tincture (1) Abdominal distension
(2) Electrolytic imbalance
(9) Cholesterinum Cholesterine Up to 0.02ml/Kg body
weight/day orally 200c (1) Abnormalliver function
(2) Cholestasis
(10) Lycopodium clavatum Herb-Lycopodium clavatum Up to 0.02ml/Kg body
weight/day orally 200c (1) Abdominal distension
(2) Cancer-related pain
c → Centesimal potency of homeopathy.
Table 2: TNM Staging, partial and complete tumor response in each cancer type.
Primary cancer
types
No. of
participants
TNM Staging of the participants No. of patients:
Complete tumor
response occurred
No. of patients:
Partial tumor
response
occurred
Diagnosed at
stage-II and
stage-III
Diagnosed at
stage-IV
Stomach 42 11 31 6 (14.29%) 16 (38.1%)
G. Bladder 40 13 27 7 (17.5%) 17 (42.5%)
Pancreas 44 9 35 8 (18.18%) 13 (29.55%)
Liver 32 13 19 7 (21.87%) 10 (31.25%)
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Figure 2: Lorenz Analysis: Distribution of tumor response in
diﬀerent cancer types.
them 4 of stomach, 2 of gall bladder, 3 of pancreatic,
and 1 of liver cancers. 158 participants (42 of stomach,
40 of gall bladder, 44 of pancreatic, and 32 of liver) were
included in the ﬁnal analysis at the end of the study. In these
participants, the diagnosis of malignancies was conﬁrmed
by histopathologicalexamination ofendoscopicbiopsiesand
cytopathologicalexamination ofCT-guidedFNAC.Incaseof
stomach, gall bladder, and pancreatic cancers, the histology
type was adenocarcinoma, and in case of liver cancer the
histologytypewashepatocellularcarcinoma(HCC).Among
the158participants, 84(53.16%)weremaleand74(46.84%)
were female. According to the AJCC TNM staging system, 39
(24.68%)were diagnosedatstage-III,and 112(70.89%)were
diagnosed at stage-IV. The participants’Karnofsky statuswas
between 40–70%, and Eastern Cooperative Oncology Group
(ECOG) status was between 2-3. Among the 39 participants
(24.68%) who were diagnosed at stage-III, 13 (33.33%)
had complete response and 16 (41.03%) had radiological
partial response. Among the 112 (70.89%) participants who
were diagnosed at stage-IV, 12 (10.71%) had radiological
complete response and 38 (33.93%) had radiological partial
response (Tables 2 and 3,F i g u r e s1, 2,a n d3). In this
s t u d y ,n oa d v e r s es i d ee ﬀects were observed from the drug
Psorinum. However, very few patients reported to have
mild oral irritation and skin itching which were successfully4 Evidence-Based Complementary and Alternative Medicine
Table 3: Survival outcomes in each cancer type.
Primary organ
aﬀected
No. of
patients Male Female Survived at
least 1 year
Survived at
least 2 years
Survived at
least 3 years
Survived at
least 4 years
Survived at
least 5 years
Stomach 42 22 20 34 24 21 20 16 (38.1%)
G. Bladder 40 21 19 32 25 20 18 15 (37.5%)
Pancreas 44 24 20 34 28 27 21 17 (38.64%)
Liver 32 17 15 26 22 19 17 14 (43.75%)
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Figure 3: Kaplan Meier survival analysis in diﬀerent cancer types.
controlled by the supportive cares. Psorinum Therapy was
also eﬀective in improving the disease symptoms and the
quality of life of the participants. At least 60% participants
ofstage-IIIandatleast45%participantsofstage-IV reported
thatthe therapywaseﬀectiveinreducing theircancer-related
pain, cough, dysponea, nausea and vomiting, fatigue, con-
stipation and improving appetite, and weakness. These were
also conﬁrmed after examining the participants clinically.
Improvements were also observed in the lab investigations
like Complete Blood Count (CBC), Liver Function Test
(LFT), Kidney function test, AFP level, and CA 19.9. These
lab investigations were done as a part of their routine clinical
check ups. Among the 158 participants, 98 (62.03%) were
aged 65 years or more. Better outcomes were observed
among the participants below 65 years of age than the
participants who were over the age of 65. The outcomes did
not vary signiﬁcantly while considering gender. Figures 4(a)
and 4(b) show complete tumor response in one stomach
and one gall bladder cancer patients, respectively, who were
treated through Psorinum Therapy.
4.Discussionand Conclusion
Many studies were published on the role of complementary
and alternative medicines in treating cancer patients. Some
studies support the CAM therapies to be beneﬁcial for
palliative cancer cares [30–35]. However, very few of the
published reports support their eﬃcacy with regard to
the primary care of cancer. According to our knowledge,
the clinical study, reported here, is the only prospective
study that intrigued a fair number of complete and partial
tumor responses along with impressive survival outcomes
in treating patients with stomach, gall bladder, pancreatic,
and liver cancers through psorinum therapy. Previously,
interviews were conducted on 300 biopsy-proved cancer
patients of Psorinum Therapy. The primary purpose of the
study was to ascertain the patients’ and/or their caregivers’
view on this CAM therapy. The survey showed the patients
hadtriedPsorinum Therapy mainly duetonootheravailable
treatment options, ﬁnancial constraints, frustration with the
conventional cancer treatments, and belief in the eﬃcacy
of the Psorinum Therapy. According to the survey, among
the 300 cancer patients, 195 (65%) had consulted their
oncologists before trying the therapy [17]. This therapy can
be easily replicated by other practitioners in diﬀerent clinical
centers due to the following advantages.
The reagent to prepare the drug Psorinum is available.
The speciﬁc dosing and the medicinal power are established.
The medicine administration technique is easy as it can be
taken orally.
The supportive treatments are adopted from the allo-
pathicstreams. Thesupportivetreatmentswithhomeopathic
medicines are done by speciﬁc ailment versus speciﬁc
medicine concept instead of the concept of speciﬁc patient
versus speciﬁc medicine, making the homeopathic support-
ive cares easier to replicate. In a nutshell, we should remem-
berthat,158participantsofhistopathologyorcytopathology
conﬁrmed stomach, gall bladder, pancreatic, and liver can-
cers were includedin theﬁnal analysis attheendof thestudy.
According to the AJCC TNM staging system, 39 (24.68%)
werediagnosedatstage-IIIand112(70.89%)werediagnosed
at stage-IV. The participants Karnofsky status was between
30–60% and ECOGstatus was between 2-3. The participants
received the drugPsorinum along with allopathic and home-
opathic supportive treatments without trying conventional
or any other investigational cancer treatments. According
to the RECIST criteria, radiological complete response
occurred in 28 (17.72%) and partial response occurred inEvidence-Based Complementary and Alternative Medicine 5
Baseline CT: showing stomach mass Follow-up CT: showing complete
regression of the mass
(a)
Baseline CT: showing GB mass Follow-up CT: showing complete
regression of the mass
(b)
Figure 4: (a) Showing complete tumor response of a stomach cancer patient who underwent Psorinum Therapy. (b) Showing complete
tumor response of a gall bladder cancer patient who underwent PsorinumTherapy.
56 (35.44%) participants. The limitation of this study is
that it did not have any placebo or treatment control arm;
therefore, it cannot be concluded that Psorinum Therapy is
eﬀective in improving the survival and the quality of life of
the participants due to the academic rigours of the scientiﬁc
clinical trials. This study also cannot rule out the eﬀects
of the implemented allopathic and homeopathic supportive
measures in the observed results. However, the results of
the study showed a fair number of complete and partial
tumor responses along with impressive survival outcomes in
diﬃculttotreatcancertypes.Therefore,randomizeddouble-
blind clinical trial, detailed molecular, pharmacokinetics,
and pharmacodynamics studiesshould beconductedforfur-
therscientiﬁcexplorationofthisalternativecancertreatment
to determine if it can be integrated into the mainstream
oncology.
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